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Risk reducing salpingectomy BRCA1 carcinomaIntroductionRecent studies highlight the importance of the fallopian tube as a
putative site of origin for serous ovarian carcinomas, previously felt
to arise exclusively from ovarian tissue. The initial association
emerged from the pathologic analysis of BRCA mutation carriers un-
dergoing risk-reducing bilateral salpingo-oophorectomy (RRBSO),
where a high percentage of incidentally diagnosed cancers and can-
cer precursor lesions were discovered in the distal fallopian tube
(Herzog and Dinkelspiel, 2013; Crum et al., 2012; Kwon et al.,
2013). These ﬁndings have enlivened the discussion on the appro-
priate management of women at high risk for ovarian cancer,
proposing risk-reducing bilateral salpingectomy with delayed bi-
lateral oophorectomy as a reasonable alternative to RRBSO and a
means to diminish postoperative sequelae related to estrogen-
deﬁciency. We searched MEDLINE using PubMed for all English
language articles from 1980 to 2014, with search terms including
“ovarian cancer,” “fallopian tube cancer,” “BRCA,” “risk reducing
oophorectomy” and “risk-reducing salpingectomy.” To date, all re-
ported cases of occult serous carcinoma found in the fallopian tube
have been in women with known BRCA mutations who underwent
RRBSO. Here, we report a case of invasive high-grade serous carci-
noma found in the fallopian tube of a woman with a BRCA1 muta-
tion who underwent a risk-reducing salpingectomy with ovarian
preservation.☆ Financial disclosures: None.
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A 41-year-old (gravid 1, para 1) Ashkenazi Jewishwoman presented
for ovarian cancer risk assessment. Her personal history was signiﬁcant
for a deleterious BRCA1mutation, 187delAG. The patient's mother and
maternal aunt were positive for the same mutation and her maternal
aunt had bilateral premenopausal breast cancer. The patient underwent
an endovaginal ultrasound and serum CA-125 measurement, both of
whichwere normal. A pelvic examperformed at this visitwas alsowith-
in normal limits.
At the conclusion of the initial consultation, the patient was advised
that the currently accepted guidelines recommend RRBSO for women
with hereditary breast and ovarian cancer syndrome by age 40 or
when childbearing is complete (American College of Obstetricians and
Gynecologists, 2008, 2009). The patient was reluctant to have her ova-
ries removed due to anticipated health and quality of life consequences,
and after extensive discussion, elected to undergo a risk-reducing
salpingectomy nine months following the original consultation, with
the intention of having her ovaries removed at a second surgery per-
formed closer to initiation of natural menopause.
The patient underwent an uncomplicated minimally invasive
salpingectomy. Intraoperatively, the uterus, ovaries and fallopian
tubes were noted to be grossly normal. Histologic examination of
the left fallopian tube revealed an in situ and invasive high-grade se-
rous adenocarcinoma, measuring 2mm in greatest dimension. Pelvic
washings were negative for malignant cells.
The pathology results, along with the next steps in management,
were reviewed with the patient at a follow-up visit. The patient
underwent minimally invasive hysterectomy, bilateral oophorecto-
my, and staging, including pelvic and para-aortic lymph node dissec-
tion and omentectomy. The pathology from the second procedurewas all
negative for malignancy. The patient completed six cycles of platinum-
based chemotherapy. She hasno evidence of disease 7 months sincediag-
nosis and is maintained on oral hormone replacement.Discussion
The current standard of care for women with hereditary breast and
ovarian cancer is RRBSO at 40 years of age or upon completion of child-
bearing (American College of Obstetricians and Gynecologists, 2008,
2009). The rationale behind this recommendation is that the risk of
ovarian cancer increases signiﬁcantly after age 40 in women withe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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ovarian cancer by age 50 (American College of Obstetricians and Gyne-
cologists, 2009). The risk of premenopausal ovarian cancer in BRCA2
mutation carriers is considerably lower, with 3% of women in this
group developing ovarian cancer by age 50, although the risk of devel-
oping breast cancer before the age of 50 is still quite high, at 26–34%
(American College of Obstetricians and Gynecologists, 2009). Bilateral
salpingo-oophorectomy has been shown to lessen the risk of ovarian
and fallopian tube cancer by 80–90%, and the risk of breast cancer by
50% in BRCAmutation carriers (Rebbeck et al., 2009). Many women in
this high-risk population are reluctant to undergo RRBSO due to poten-
tial effects of early menopause, including osteoporosis and cardiovascu-
lar disease (Kwon et al., 2013), aswell as anticipated negative impact on
quality of life, especially in women previously diagnosed with hormone
receptor positive breast cancer, and therefore unable to take hormone
replacement. Perhaps as a direct result of these concerns, only 60–70%
of BRCA mutation carriers are estimated to have undergone RRBSO
(Kwon et al., 2013), and only 43% of those less than age forty (Friebel
et al., 2007).
With newfound insight that a signiﬁcant percentage of serous carcino-
mas originate in the fallopian tube, salpingectomy with delayed oopho-
rectomy has been proposed as an alternative risk reduction strategy for
premenopausal women with deleterious BRCAmutations. In an effort to
deﬁne the beneﬁts associated with bilateral salpingectomy versus
salpingo-oophorectomy, Kwon et al. (2013) developed a simulation
model to compare different strategies for risk reduction in BRCAmuta-
tion carriers, evaluating incremental cost-effectiveness ratio. The inves-
tigators compared the following three strategies: 1) RRBSO, 2) bilateral
salpingectomy, and 3) bilateral salpingectomy with delayed oophorec-
tomy. They found RRBSO to be the superior strategy for BRCAmutation
carriers, with associated lowest cost and highest life expectancy. Inter-
estingly, salpingectomy at age 40 followed by delayed oophorectomy
at age 50 had the highest life expectancy when quality-of-life measures
were taken into account. In this study, risk-reducing salpingectomywas
associated with a 60% reduction in BRCA-associated mullerian cancer
risk, compared to an 80% decrease with RRBSO. While the investigators
maintained that the standard of care remains RRBSO by age 40, they
concluded that salpingectomy with delayed oophorectomy might be a
reasonable option for premenopausal women who are reluctant to un-
dergo RRBSO. They emphasize that this strategy would reduce the risk
of BRCA-associated mullerian cancer in this high-risk population with-
out increasing the risk of death from cardiovascular disease, and with
the least negative impact on the patients' quality of life (Kwon et al.,
2013). There are several ongoing clinical trials investigating the efﬁcacy
of salpingectomy in reducing the risk of pelvic cancer in BRCA carriers
(Centre Oscar Lambret, 2011), and comparing the rates and safety of
RRBSO with those of prophylactic salpingectomy with delayed oopho-
rectomy (PSDO) (M.D. Anderson Cancer Center, 2013). These studies,
in addition to British Columbia's OVCARE initiative to remove fallopian
tubes at every hysterectomy (Finlayson, 2011),will play an integral role
in providing the data needed to appropriately counsel premenopausal
high-risk patients.
While some experts have cautioned that it is “premature” to offer
salpingectomy as a risk reduction strategy prior to evaluation of “compre-
hensive comparative data (Vaughan et al., 2011)” and “prospective cohort
studies[s] (Narod, 2013)”, offering salpingectomy to this 41 year-old
woman resulted in a diagnosis of a Stage IA grade 3 fallopian tube cancer.
Had salpingectomy not been proposed as an option, no risk reducing sur-gery would have been performed as yet, and the cancer would have had
the potential to metastasize, increasing the stage of her disease, and neg-
atively impacting her survival.
While recent literature reports a signiﬁcant rate of occult cancer found
at the time of risk-reducing salpingo-oophorectomy (Manchanda et al.,
2011; Powell et al., 2011), this is theﬁrst report of occult cancer diagnosed
at risk reducing salpingectomy, and illustrates the importance of ﬂexibil-
ity and compromise in counseling women at increased genetic risk of
ovarian cancer. While it is critical to stress the importance of risk-
reducing surgery in this high risk population, management must be indi-
vidualized for each patient, as a rigid approach which alienates young
mutation carriers could result in missed opportunities to reduce cancer
risk. When proposed, risk-reducing salpingectomy is offered as the ﬁrst
step in a two-part risk reduction strategy,withplan for delayed oophorec-
tomy, and not as a substitute for RRBSO.
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